Provision of specialized medical care in the Republic of Sakha (Yakutia) to patients with cognitive disorders
https://doi.org/10.25789/YMJ.2024.87.10
Abstract
The article presents an analysis of statistical data on dementia from official sources of state statistics, medical and scientific organizations, as well as the provision of specialized medical care in the Republic of Sakha (Yakutia) to patients with cognitive impairment.
About the Authors
T. K. Davydova
Yakut Science Centre of Complex Medical Problems
Russian Federation
Russian Federation
Davydova Tatyana Kimovna – PhD, visiting research fellow, head of the lab.
A. N. Romanova
Yakut Science Centre of Complex Medical Problems
Russian Federation
Russian Federation
Romanova Anna Nikolaevna – MD, Director.
O. V. Tatarinova
Yakut Science Centre of Complex Medical Problems; Clinical Hospital No 3
Russian Federation
Russian Federation
Tatarinova Olga Viktorovna – MD, senior researcher; chief physician Clinical Hospital No 3
T. Ya. Nikolaeva
Yakut Science Centre of Complex Medical Problems; Medical Sciences M.K. Ammosov North Eastern Federal University
Russian Federation
Russian Federation
Nikolaeva Tatiana Yakovlevna – MD, head of the Department of Medical Sciences M.K. Ammosov NEFU
References
1. Koberskaya N.N. Alzheimer's disease: new diagnostic criteria and therapeutic aspects depending on the stage of the disease // Medical Council. 2017. (10):18-24. https://doi.org/10.21518/2079-701X-2017-10-18-24
2. Tappakhov A.A., Nikolaeva T.Ya., Struchkov A.M., Popova T.E. Alzheimer's disease in the Republic of Sakha (Yakutia): realities and expectations // Yakut Medical Journal. 2023. No. 4.:88-92. DOI: 10.25789/YMJ.2023.83.10
3. Darbà J, Marsà A. Hospital incidence, mortality and costs of Alzheimer's disease in Spain: a retrospective multicenter study. 2021. Oct;21(5):1101-1106. doi: 10.1080/14737167.2020.1820328.
4. Connexins and pannexins in Alzheimer's disease / Giaume C, Sáez JC, Song W. [et al.] // Neurosci Lett. 2019 Mar 16:695:100-105.
5. Global status report on the public health response to dementia: еxecutive summary. 2021. P. 3.
6. High performance plasma amyloid-β biomarkers for Alzheimer's disease / Akinori Nakamura, Naoki Kaneko, Victor L Villemagne et al./ //Nature. 2018 Feb 8;554(7691):249-254.
7. Mortality of Alzheimer's Disease and Other Dementias in China: Past and Future Decades / Lv B., Liang L, Chen A, Yang H., Zhang X., Guo F., Qian H.// Int J Public Health. 2023. Feb 3:68:1605129.
8. Trends in mortality from Alzheimer's disease in Brazil / Paschalidis M, Konstantyner TCRO, Simon SS [et al.] //Epidemiol. Serv Saude. 2000-20192023 Mar-Jun;32(2):e2022886. doi: 10.1590/S2237-96222023000200002.
9. The Alzheimer's Association. Alzheimers Dement. 2023. Apr;19(4):1598-1695. doi: 10.1002/alz.13016.
10. Wong SL, Gilmour H, Ramage-Morin PL. Alzheimer's disease and other dementias in Canada// Health Rep. 2016. May 18;27(5):11-6.
11. www.lvrach.ru/partners/alzepil/15438646
12. https://14.rosstat.gov.ru/
Review
For citations:
Davydova T.K., Romanova A.N., Tatarinova O.V., Nikolaeva T.Ya. Provision of specialized medical care in the Republic of Sakha (Yakutia) to patients with cognitive disorders. Yakut Medical Journal. 2024;(3):52-57. https://doi.org/10.25789/YMJ.2024.87.10
Views:
13
Email this article 